Literature DB >> 30684134

Inhibition of secretory phospholipase A2 IIa attenuates prostaglandin E2-induced invasiveness in lung adenocarcinoma.

Alison L Halpern1, Patrick D Kohtz2, Jessica Y Rove2, Lihua Ao2, Xianzhong Meng2, David A Fullerton2, Michael J Weyant2.   

Abstract

Secretory phospholipase A2 IIa (sPLA2 IIa) catalyzes the production of multiple inflammatory mediators that influence the development of lung and other cancers. The most potent of these carcinogenic mediators is prostaglandin E2 (PGE2). We hypothesize that sPLA2 IIa inhibition modulates the production of PGE2, and sPLA2 IIa inhibition exerts its antineoplastic effects via downregulation of PGE2 production. We aim to evaluate these relationships via analysis of PGE2-mediated growth regulation pathways. A549 and H1650 lung adenocarcinoma cells were assayed for PGE2 production in the presence of sPLA2 IIa inhibitor. A549 and H1650 cells were treated with PGE2 and immune blotting was performed to assess ICAM-1 expression and STAT-3 activity. PGE2-induced ICAM-1 expression was measured via immunofluorescence. A549 and H1650 cells were treated with PGE2 in the presence of STAT3 inhibitor and assayed for ICAM-1 expression. A549 cells were treated with PGE2 in the presence ICAM-1 blocking antibody and assayed for invasion. PGE2 stimulation significantly increased the invasiveness and proliferation of lung adenocarcinoma (invasion p < 0.05, proliferation p < 0.05 A549 cells, p < 0.005 H1650 cells). sPLA2 IIa inhibition reduced PGE2 secretion (p < 0.05). PGE2 stimulation significantly upregulated the expression of cell adhesion molecule ICAM-1 and the phosphorylation of anti-apoptotic transcription factor STAT3 (p < 0.05). STAT3 inhibition attenuated ICAM-1 expression demonstrating the dependence of ICAM-1 on the STAT3 pathway (p < 0.05). ICAM-1 blockade attenuated the pro-invasive effects of PGE2 (p < 0.05). sPLA2 IIa inhibition attenuates the potent effects of PGE2-induced invasiveness. This is mediated by decreasing pro-inflammatory and invasion-promoting ICAM-1via the STAT-3 pathway. These data further describe how sPLA2 IIa inhibition mechanistically exerts its anticancer effects and support its use as an antineoplastic agent.

Entities:  

Keywords:  Cell signaling; Invasion; Lung cancer; Prostaglandin; sPLA2

Mesh:

Substances:

Year:  2019        PMID: 30684134     DOI: 10.1007/s11010-019-03500-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  28 in total

1.  Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

Authors:  Leslie Oleksowicz; Yin Liu; R Bruce Bracken; Krishnanath Gaitonde; Barbara Burke; Paul Succop; Linda Levin; Zhongyun Dong; Shan Lu
Journal:  Prostate       Date:  2011-11-29       Impact factor: 4.104

2.  Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.

Authors:  M Wang; F-Y Hao; J-G Wang; W Xiao
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014       Impact factor: 3.507

3.  Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.

Authors:  Daine T Bennett; Xin-Sheng Deng; Jessica A Yu; Marshall T Bell; David C Mauchley; Xianzhong Meng; T Brett Reece; David A Fullerton; Michael J Weyant
Journal:  Ann Thorac Surg       Date:  2014-06-10       Impact factor: 4.330

Review 4.  Role of cyclooxygenase-2 in gastric cancer development and progression.

Authors:  Jian Cheng; Xiao-Ming Fan
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

5.  Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.

Authors:  Zhongyun Dong; Yin Liu; Kieran F Scott; Linda Levin; Krishnanath Gaitonde; R Bruce Bracken; Barbara Burke; Qihui Jim Zhai; Jiang Wang; Leslie Oleksowicz; Shan Lu
Journal:  Carcinogenesis       Date:  2010-09-13       Impact factor: 4.944

6.  Role of type IIA secretory phospholipase A2 in arachidonic acid metabolism.

Authors:  H Kuwata; H Sawada; M Murakami; I Kudo
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

Review 7.  Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe.

Authors:  Bharat B Aggarwal; R V Vijayalekshmi; Bokyung Sung
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

8.  Secreted phospholipases A2 in cancer: diverse mechanisms of action.

Authors:  Vesna Brglez; Gérard Lambeau; Toni Petan
Journal:  Biochimie       Date:  2014-10-05       Impact factor: 4.079

9.  Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules.

Authors:  Elena Kupert; Marshall Anderson; Yin Liu; Paul Succop; Linda Levin; Jiang Wang; Kathryn Wikenheiser-brokamp; Pingping Chen; Susan M Pinney; Trudy Macdonald; Zhongyun Dong; Sandra Starnes; Shan Lu
Journal:  BMC Cancer       Date:  2011-12-09       Impact factor: 4.430

10.  Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.

Authors:  Zhongyun Dong; Jaroslaw Meller; Paul Succop; Jiang Wang; Kathryn Wikenheiser-Brokamp; Sandra Starnes; Shan Lu
Journal:  Int J Oncol       Date:  2014-06-10       Impact factor: 5.650

View more
  2 in total

1.  Secretory Phospholipase A2 Digital Expression Analysis in Colon Adenocarcinoma.

Authors:  Evangelos Falidas; Eirini Kitsiouli; Despoina Spyropoulou; Evangelos Tsiambas; Asimina Kalogirou; George Tsouvelas; Stylianos Papadopoulos; Michail Mitsis; Marilena Lekka; Sofianiki Mastronikoli; Dimitrios Peschos; Odysseas Dimas; Konstantinos Vlachos
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis.

Authors:  Ada Weinstock; Karishma Rahman; Or Yaacov; Hitoo Nishi; Prashanthi Menon; Cyrus A Nikain; Michela L Garabedian; Stephanie Pena; Naveed Akbar; Brian E Sansbury; Sean P Heffron; Jianhua Liu; Gregory Marecki; Dawn Fernandez; Emily J Brown; Kelly V Ruggles; Stephen A Ramsey; Chiara Giannarelli; Matthew Spite; Robin P Choudhury; P'ng Loke; Edward A Fisher
Journal:  Elife       Date:  2021-03-15       Impact factor: 8.140

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.